Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO1998052962) OLIGONUCLEOTIDE ADJUVANT
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/1998/052962 International Application No.: PCT/US1998/010459
Publication Date: 26.11.1998 International Filing Date: 19.05.1998
Chapter 2 Demand Filed: 21.12.1998
IPC:
A61K 39/29 (2006.01) ,A61K 39/39 (2006.01) ,C07H 21/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
12
Viral antigens
29
Hepatitis virus
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
39
characterised by the immunostimulating additives, e.g. chemical adjuvants
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
H
SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21
Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Applicants:
CAULFIELD, Michael, J. [US/US]; US (UsOnly)
MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue Rahway, NJ 07065, US (AllExceptUS)
Inventors:
CAULFIELD, Michael, J.; US
Agent:
MERCK & CO., INC.; 126 East Lincoln Avenue Rahway, NJ 07065, US
Common
Representative:
MERCK & CO., INC.; 126 East Lincoln Avenue Rahway, NJ 07065, US
Priority Data:
60/047,12119.05.1997US
Title (EN) OLIGONUCLEOTIDE ADJUVANT
(FR) ADJUVANT OLIGONUCLEOTIDIQUE
Abstract:
(EN) The invention provides oligonucleotide adjuvants useful for the generation of both a cell mediated (cytotoxic T lymphocyte) response and an antibody response to an antigen presented by the administration of a vaccine. Vaccine compositions including the adjuvant and methods of vaccination using the adjuvants are also provided.
(FR) L'invention concerne des adjuvants oligonucléotidiques utiles pour provoquer à la fois une réaction à médiation cellulaire (lymphocytes T cytotoxiques) et une réaction immunitaire à un antigène présenté par l'administration d'un vaccin. Des compositions de vaccins renfermant l'adjuvant et des procédés de vaccination employant les adjuvants sont également prévus.
Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)